|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Evolution of systemic therapy of advanced hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC. | Thomas Yau Pierre Chan Richard Epstein Ronnie T Poon | 2008 | World Journal of Gastroenterology2008，14，42： | 23 |
| 2 | SARS-CoV-2 infects human neural progenitor cells and brain organoids显示文摘Dear Editor,Coronavirus disease 2019(COVID-19)caused by the novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)1 has resulted in over 13 million confirmed cases and more than 580,045 deaths across 218 countries and geographical regions as of July 16,2020.This novel coronavirus primarily causes respiratory illness with clinical manifestations largely resembling those of SARS.However,neurological symptoms including headache,anosmia,ageusia,confusion,seizure,and encephalopathy have also been frequently reported in COVID-19 patients. | Bao-Zhong Zhang Hin Chu Shuo Han Huiping Shuai Jian Deng Ye-fan Hu Hua-rui Gong Andrew Chak-Yiu Lee Zijiao Zou Thomas Yau Wutian Wu Ivan Fan-Ngai Hung Jasper Fuk-Woo Chan Kwok-Yung Yuen Jian-Dong Huang | 2020 | Cell Research2020，30，10： | 8 |
| 3 | Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients显示文摘Dear Editor,The ongoing coronavirus disease 2019(COVID-19)pandemic caused by severe acute respiratory syndrome coronavirus-2(SARSCoV-2)is a serious threat to global public health,and is imposing severe burdens on human society.Several candidate vaccines against SARS-CoV-2 are now undergoing clinical trials.The Spike(S)protein of SARS-CoV-2 is widely considered as a promising antigen.However. | Bao-zhong Zhang Ye-fan Hu Lin-lei Chen Thomas Yau Yi-gang Tong Jing-chu Hu Jian-piao Cai Kwok-Hung Chan Ying Dou Jian Deng Xiao-lei Wang Ivan Fan-Ngai Hung Kelvin Kai-Wang To Kwok Yung Yuen Jian-Dong Huang | 2020 | Cell Research2020，30，8： | 5 |
| 4 | Development of Hong Kong Liver Cancer Staging System with Treatment Stratification for Patients with Hepatocellular Carcinoma显示文摘 | Thomas Yau Vikki Y.F. Tang Tzy-Jyun Yao Sheung-Tat Fan Chung-Mau Lo Ronnie T.P. Poon | 2014 | Gastroenterology2014，，： | 5 |
| 5 | A Subpopulation of CD26 + Cancer Stem Cells with Metastatic Capacity in Human Colorectal Cancer显示文摘 | Roberta Pang Wai Lun Law Andrew C.Y. Chu Jensen T. Poon Colin S.C. Lam Ariel K.M. Chow Lui Ng Leonard W.H. Cheung Xiao R. Lan Hui Y. Lan Victoria P.Y. Tan Thomas C. Yau Ronnie T. Poon Benjamin C.Y. Wong | 2010 | Cell Stem Cell2010，，6： | 4 |
| 6 | Survival analysis of breast cancer liver metastasis treated by hepatectomy: A propensity score analysis for Chinese women in Hong Kong显示文摘Background: Survival of patients with breast cancer liver metastasis is very poor. This study aimed to analyze the survival outcome of hepatectomy for this patient population. Methods: From January 1995 to December 2014, 2522 patients with liver cancer received hepatectomy at our hospital. Twenty-one of them, all female, received the operation for breast cancer liver metastasis. Performance was compared with patients with colorectal liver metastasis treated with hepatectomy after propensity score analysis in a ratio of 1:3. Results: Twenty-one patients received hepatectomy for breast cancer. After propensity score matching, 63 patients who had hepatectomy for colorectal cancer were selected for comparison. There was no significant difference in immediate or short-term outcomes between the two groups of patients in terms of operative time, blood loss and surgical morbidities. All patients with breast cancer had R0 resection. No hospital death occurred. After hepatectomy, the 1-, 3- and 5-year overall survival rates were 100.0%, 58.9% and 58.9% respectively in patients with breast cancer. The 1-, 3- and 5-year overall survival rates were 95.0%, 57.2% and 39.7% respectively in patients with colorectal cancer (P = 0.572). On multivariate analysis, triple negative status was the only independent poor prognostic factor in breast cancer liver metastasis (OR = 6.411;95% CI: 1.351–30.435;P = 0.019). Conclusions: Hepatectomy is a safe and effective way of treating breast cancer liver metastasis at experienced centers where multidisciplinary adjuvant treatments are available. It can be considered more frequently as part of the multidisciplinary care for this patient population. | Tan To Cheung Kenneth SH Chok Albert CY Chan Simon HY Tsang Wing Chiu Dai Thomas CC Yau Ava Kwong Chung Mau Lo | 2019 | Hepatobiliary & Pancreatic Diseases International2019，18，5： | 3 |
| 7 | Endogenous mono-ADP-ribosylation mediates smooth muscle cell proliferation and migration via protein kinase N-dependent induction of c-fos expression显示文摘 | YAU L LlTCHIE B THOMAS 5 | 2003 | fur[Biochem2003，270，1： | 1 |
| 8 | Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease显示文摘 | Thomas Yau Hilda Wong Pierre Chan T. J. Yao R. Pang T. T. Cheung S. T. Fan Ronnie T. Poon | 2012 | Investigational New Drugs2012，，6： | 1 |
| 9 | Molecular mechanisms of cystallization and defect formation显示文摘 | YAU S T THOMAS B R VEKILOV P G | 2000 | Physical Review Letters2000，85，： | 1 |
| 10 | A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma显示文摘 | Thomas Yau P. N. Cheng Pierre Chan William Chan Li Chen Jimmy Yuen Roberta Pang S. T. Fan Ronnie T. Poon | 2013 | Investigational New Drugs2013，，1： | 1 |
| 11 | Surveillance in Stage I Seminoma Patients: A Long-Term Assessment显示文摘 | Sebastian Cummins Thomas Yau Robert Huddart David Dearnaley Alan Horwich | 2009 | European Urology2009，，4： | 1 |
| 12 | The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosis显示文摘 | Joanne Chiu Yuen Fong Tang Tzy‐Jyun Yao Ashley Wong Hilda Wong Roland Leung Pierre Chan Tan To Cheung Albert C. Chan Roberta Pang Sheung‐Tat Fan Ronnie Poon Thomas Yau | 2012 | Cancer2012，，21： | 1 |
| 13 | Management of advanced hepatocellular carcinoma in era of targed therapy显示文摘 | Thomas Yau Pierre Chan Richard Epstain | 2009 | Liv er International2009，，： | 1 |
| 14 | Endogenous mono- ADP-ribosylation mediates smooth muscle cell proliferation and migration via protein kinase N-dependent induction of c-fos expression 显示文摘 | Yau L Litchie B Thomas S | 2003 | Eur J Biochem2003，270，： | 1 |
| 15 | Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?显示文摘 | Joanne Chiu Thomas Yau Marcus Bahra | 2012 | Gastroenterology Research and Practice2012，，： | 1 |
| 16 | Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid Carcinoma Patients with Detectable Thyroglobulin after Radioiodine Ablation?显示文摘 | Hilda Wong Kai Wong Thomas Yau Vikki Tang Roland Leung Joanne Chiu Brian Lang | 2012 | Annals of Surgical Oncology2012，，11： | 1 |
| 17 | Outcome of laparoscopic versus open hepatectomy for colorectal liver metastases显示文摘 | Tan To Cheung Ronnie T. P. Poon Wai Key Yuen Kenneth S. H. Chok Simon H. Y. Tsang Thomas Yau See Ching Chan Chung Mau Lo | 2013 | ANZ J Surg2013，，11： | 1 |
| 18 | The Hong Kong consensus statements on unresectable hepatocellular carcinoma:narrative review and update for 2021显示文摘Background and Objective:Hong Kong,like many parts of Asia,faces a high burden of hepatocellular carcinoma(HCC)caused by high endemic rates of hepatitis B virus infection.Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical,transarterial,ablative,radiotherapeutic and systemic modalities.This publication summarizes the latest evidence-based recommendations on how these modalities should be used.Methods:In two meetings held in 2020,a multidisciplinary panel of surgeons,oncologists and interventional radiologists performed a narrative review of evidence on the management of HCC,with an emphasis on treatment of HCC not amenable to surgical resection.Close attention was paid to new evidence published since the previous version of these statements in 2018.Key Content and Findings:The expert panel has formulated 60 consensus statements to guide the staging and treatment of unresectable HCC.Since the previous version of these statements,considerable additions have been made to the recommendations on use of targeted therapies and immunotherapies because of the large volume of new evidence.Conclusions:Our consensus statements offer guidance on how to select HCC patients for surgical or non-surgical treatment and for choosing among non-surgical modalities for patients who are not candidates for resection.In particular,there is a need for more evidence to aid physicians in the selection of second-line systemic therapies,as currently most data are limited to patients with disease progression on first-line sorafenib. | Tan-To Cheung Simon Chun-Ho Yu Stephen L.Chan Ronnie T.P.Poon Philip Kwok Ann-Shing Lee Anna Tai Derek Tam Chin-Cheung Cheung Tak-Wing Lai Nam-Hung Chia Ada Law Tracy Shum Yim-Kwan Lam Vince Lau Victor Lee Charing Chong Chung-Ngai Tang Thomas Yau | 2023 | Hepatobiliary Surgery and Nutrition2023，12，3： | 0 |
| 19 | Colon cancer in a patient with underlying aplastic anemia: A clinical challenge显示文摘The association of gastrointestinal malignancy with aplastic anemia has rarely been reported in the literature. Although it is not clear whether there is any direct relationship between aplastic anemia and gastrointestinal cancers, a retrospective analysis did suggest the notion that patients with aplastic anemia might have a higher incidence of colorectal cancer. Here, we report the diagnostic and therapeutic challenges in managing a patient with aplastic anemia and advanced colorectal cancer. Early diagnosis is challenging due to overlapping symptomatology and clinical features, increased risk of diagnostic procedures, and confounding complications arising from aplastic anemia and its treatment. A high index of suspicion and multidisciplinary input are essential. | Hilda Wong Pierre Chan Thomas Yau | 2012 | World Journal of Clinical Oncology2012，3，2： | 0 |
| 20 | The Hong Kong consensus recommendations on the diagnosis and management of pancreatic cystic lesions显示文摘Background:The finding of pancreatic cystic lesions(PCL)on incidental imaging is becoming increasingly common.International studies report a prevalence of 2.2-44.7%depending on the population,imaging modality and indication for imaging,and the prevalence increases with age.Patients with PCL are at risk of developing pancreatic cancer,a disease with a poor prognosis.This publication summarizes recommendations for the diagnosis and management of PCL and post-operative pancreatic exocrine insufficiency(PEI)from a group of local specialists.Methods:Clinical evidence was consolidated from narrative reviews and consensus statements formulated during two online meetings in March 2022.The expert panel included gastroenterologists,hepatobiliary surgeons,oncologists,radiologists,and endocrinologists.Results:Patients with PCL require careful investigation and follow-up due to the risk of malignant transformation of these lesions.They should undergo clinical investigation and pancreas-specific imaging to classify lesions and understand the risk profile of the patient.Where indicated,patients should undergo pancreatectomy to excise PCL.Following pancreatectomy,patients are at risk of PEI,leading to gastrointestinal dysfunction and malnutrition.Therefore,such patients should be monitored for symptoms of PEI,and promptly treated with pancreatic enzyme replacement therapy(PERT).Patients with poor response to PERT may require increases in dose,addition of a proton pump inhibitor,and/or further investigation,including tests for pancreatic function.Patients are also at risk of new-onset diabetes mellitus after pancreatectomy;they should be screened and treated with insulin if indicated.Conclusions:These statements are an accurate summary of our approach to the diagnosis and management of patients with PCL and will be of assistance to clinicians treating these patients in a similar clinical landscape. | Tan-To Cheung Yuk Tong Lee Raymond Shing-Yan Tang Wong Hoi She Kai Chi Cheng Chin Cheung Cheung Keith Wan Hang Chiu Kenneth Siu Ho Chok Wing Sun Chow Tak Wing Lai Wai-Kay Seto Thomas Yau | 2023 | Hepatobiliary Surgery and Nutrition2023，12，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员